Trial Profile

A Phase I/IIa (Phase 1/Phase 2a), Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 01 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Surabgene lomparvovec (Primary)
Indications Wet age-related macular degeneration
Focus Adverse reactions
Sponsors REGENXBIO

Most Recent Events

28 Mar 2024 According to a REGENXBIO Media Release, two year data of this trial were published in The Lancet.
28 Mar 2024 Results presented in a REGENXBIO Media Release.
27 Mar 2024 Results assessing the safety and efficacy of subretinal injection of RGX-314 in patients with neovascular age-related macular degeneration, published in the Lancet.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com